Search results
Results from the WOW.Com Content Network
The WHO Model List of Essential Medicines for Children (aka Essential Medicines List for Children [1] or EMLc [1]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe in children up to twelve years of age to meet the most important needs in a health system. [2] [3]
[13] [15] Pneumonia is also the leading cause of death in children less than five years of age in low income countries. [15] The most common cause of pneumonia is pneumococcal bacteria, Streptococcus pneumoniae accounts for 2/3 of bacteremic pneumonias. [16] Invasive pneumococcal pneumonia has a mortality rate of around 20%. [14]
The FDA approved only the five-mg, twice-daily dose on the grounds that a higher dose was not considered to have an adequate risk-to-benefit ratio. [34] In September 2020, the FDA approved tofacitinib for the treatment of children and adolescents two years of age and older with active polyarticular course juvenile idiopathic arthritis. [35]
The inputs for each of these variables and the ultimate interpretation of the risk premium value differs depending on the application as explained in the following sections. Regardless of the application, the market premium can be volatile as both comprising variables can be impacted independent of each other by both cyclical and abrupt changes ...
In a post-marketing surveillance evaluating safety in 2006 children with acute otitis media treated with cefditoren (median daily dose: 10.0 mg/kg with a median total treatment period of 7 days), the incidence of adverse reactions was 1.79%, without unexpected or serious adverse drug reactions reported.
The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. ( CID 636379 from PubChem ) The prodrug form faropenem medoxomil [ 4 ] (also known as faropenem daloxate ) has been licensed from Daiichi Asubio Pharma by Replidyne , which plans to market it in conjunction with Forest Pharmaceuticals.
The RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) was a multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erdosteine 300 mg/bid added to usual maintenance therapy vs. placebo over 12-months, a period long enough to avoid bias due to seasonal ...
Budesonide, sold under the brand name Pulmicort, among others, is a steroid medication. [8] It is available as an inhaler , nebulization solution , pill , nasal spray , and rectal forms . [ 8 ] [ 9 ] The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD).